Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock: Is It Too Late to Buy?

VRTX stock may have little upside, but a Gilead Sciences (NASDAQ:GILD) buyout of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be in play.

Posted in HADE Platform, Healthcare & Biotech, Hot Stocks, Members, Mergers & Acquisitions | Tagged , , , | Leave a comment

What Pfizer Inc (NYSE:PFE), Intel Corporation (NASDAQ:INTC), & Gilead Sciences (NASDAQ:GILD) Have In Common

Pfizer (NYSE:PFE) & Intel Corporation (NASDAQ:INTC) paid big bucks for growth, but Mobileye NV (NYSE:MBLY) is a bet on innovation.

Posted in Hot Stocks, Mergers & Acquisitions | Tagged , , , , , , , | Leave a comment

Why Gilead Sciences Inc (NASDAQ:GILD) Stock Owners Shouldn’t Expect Acquisitions

Gilead Sciences Inc does not need to acquire for GILD stock to reverse course and trade higher. Brian & Liam take two angles on Gilead stock.

Posted in Biotech Hunter, Healthcare & Biotech, Members | Tagged , | Leave a comment

1 Bullish Takeaway From Gilead Sciences (NASDAQ:GILD) Stock After Earnings

Gilead Sciences’ guidance was horrible, & GILD stock should be down 15%. There’s a good reason it only fell 5%, and why Gilead stock will recover.

Posted in Healthcare & Biotech, Members, Timely Analysis | Tagged , | Leave a comment

Why Gilead Sciences, Inc (NASDAQ:GILD) HCV Franchise Is Completely Worthless!

GILD stock does not support Gilead Sciences’ HCV franchise, its $31 billion in cash, and significantly undervalues its HIV franchise.

Posted in Editor's Pick, Healthcare & Biotech, Members | Tagged , | 1 Comment

Why IBM, AMGN, GOOGL, & GILD Have Little to Gain With Trump In Charge

GILD stock, AMGN stock, GOOGL stock, & IBM stock may not gain much from a reduction in the corporate tax rate, but not all are bad investments.

Posted in BNL Market Analytics, Members, Timely Analysis | Tagged , , , , , , , , , | Leave a comment

Celgene (CELG), Valeant (VRX), Acadia (ACAD), & Gilead Sciences (GILD) Outlook On Drug Pricing Concerns

How Donald Trump’s stance on drug prices will affect each of BNL Finance covered biotechs: CELG, VRX, ACAD, JAZZ, and GILD.

Posted in Healthcare & Biotech, Members, Stock Ratings, Timely Analysis | Tagged , , , , , , , , , | Leave a comment